The CEO of Moderna told Reuters on Wednesday that an Omicron-specific booster could be ready by August, but the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.
Moderna recently began clinical trials for a booster dose specifically designed to target Omicron but initial results from studies in monkeys show the Omicron-specific shot may not offer stronger protection than a new dose of the existing vaccine.